Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31711988 | 0.91 | NPFFR1 (0.50) | CYP3A4CYP2D6NPFFR1NPFFR2AKT1 | |
| SCHEMBL21411122 | 0.84 | NPFFR1 (0.52) | CYP3A4CYP2D6NPFFR1NPFFR2AKT1 | |
| SCHEMBL21410757 | 0.82 | NPFFR1 (0.51) | CYP3A4CYP2D6NPFFR1NPFFR2AKT1 | |
| SCHEMBL16196924 | 0.81 | AKT1 (0.46) | CYP2D6NPFFR1NPFFR2AKT1KMT2A | |
| SCHEMBL22875360 | 0.80 | NPFFR1 (0.46) | CYP3A4CYP2D6CYP2C9CYP2C19NPFFR1 | |
| SCHEMBL10500225 | 0.79 | CYP2D6 (0.63) | CYP3A4CYP2D6CYP2C9CYP2C19LMNA | |
| SCHEMBL31252257 | 0.79 | AKT1 (0.37) | CYP2C9CYP2C19AKT1KMT2AMEN1 | |
| SCHEMBL25227496 | 0.78 | HTT (0.43) | CYP2C19AKT1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18306722 | 0.78 | LMNA (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19NPFFR1 | |
| SCHEMBL22961965 | 0.76 | CYP2D6 (0.50) | CYP3A4CYP2D6CYP2C9CYP2C19NPFFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2023-01-19 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-9447106-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BEIGENE, LTD. (KY) | 2016-09-20 | — | — | US | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
| EP-2989106-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | Beigene, Ltd. (KY) | 2016-03-02 | — | — | EP | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2015-09-17 | — | — | US | disclosed |
| WO-2014173289-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2014-10-30 | — | — | WO | disclosed |
| US-5981545-A | FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1999-11-09 | — | — | US | disclosed |
| EP-0427390-B1 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1996-03-27 | — | — | EP | disclosed |
| EP-0427390-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | CYP3A4 2500/4885CYP2D6 1942/4885CYP2C9 2177/4885 |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | CYP3A4 1961/4885CYP2D6 3815/4885CYP2C9 3410/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | CYP3A4 1961/4885CYP2D6 3815/4885CYP2C9 3410/4885 |
| US-20150259354-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | CYP3A4 2587/4885CYP2D6 2309/4885CYP2C9 2155/4885 |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | CYP3A4 2587/4885CYP2D6 2309/4885CYP2C9 2155/4885 |
| US-20230013862-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | CYP3A4 2500/4885CYP2D6 1942/4885CYP2C9 2177/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | CYP3A4 4516/4885CYP2D6 4171/4885CYP2C9 4619/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | CYP3A4 2500/4885CYP2D6 1942/4885CYP2C9 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.